ATMP trials classification by disease and development phase globally 2016

This statistic shows the distribution of advanced therapy medicinal product (ATMP) trials worldwide as of 2016, by disease area and phase of development. The share of cancer related ATMP trials in phase I and I/II was 24.2 percent.

Classification of advanced therapy medicinal product (ATMP) trials worldwide as of 2016, by disease area and phase

Characteristic	Phase I and I/II	Phase II II/III	Phase III	NA	Total
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

April 2016

More information

Region

Worldwide

Survey time period

as of 2016

Supplementary notes

This statistic includes clinical trials from following databases: EudraCT (EU Drug Regulating Authorities Clinical Trials), ClinicalTrials.gov, and ICTRP (International Clinical Trials Registry Platform of the World Health Organization).
The table shows the number of ATMP trials in each disease area: cancer, cardiovascular diseases, immune system/inflammation, musculoskeletal system, neurology, GI diseases and diabetes, ophthalmology, pulmonology, dermatology, haematology, and others. In addition, it shows the percentage of ATMPs targeting every indication by phase of development.
* GI diseases: gastrointestinal diseases.

Citation formats